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Abstract
DNA from two novel HPV genotypes, HPV-150 and HPV-151, isolated from hair follicles of immuno-competent individuals,
was fully cloned, sequenced and characterized. The complete genomes of HPV-150 and HPV-151 are 7,436-bp and 7,386-bp
in length, respectively. Both contain genes for at least six proteins, namely E6, E7, E1, E2, L2, L1, as well as a non-coding
upstream regulatory region located between the L1 and E6 genes: spanning 416-bp in HPV-150 (genomic positions 7,371 to
350) and 322-bp in HPV-151 (genomic positions 7,213 to 148). HPV-150 and HPV-151 are phylogenetically placed within the
Betapapillomavirus genus and are most closely related to HPV-96 and HPV-22, respectively. As in other members of this
genus, the intergenic E2-L2 region is very short and does not encode for an E5 gene. Both genotypes contain typical zinc
binding domains in their E6 and E7 proteins, but HPV-151 lacks the regular pRb-binding core sequence within its E7 protein.
In order to assess the tissue predilection and clinical significance of the novel genotypes, quantitative type-specific real-time
PCR assays were developed. The 95% detection limits of the HPV-150 and HPV-151 assays were 7.3 copies/reaction (range
5.6 to 11.4) and 3.4 copies/reaction (range 2.5 to 6.0), respectively. Testing of a representative collection of HPV-associated
mucosal and cutaneous benign and malignant neoplasms and hair follicles (total of 540 samples) revealed that HPV-150 and
HPV-151 are relatively rare genotypes with a cutaneous tropism. Both genotypes were found in sporadic cases of common
warts and SCC and BCC of the skin as single or multiple infections usually with low viral loads. HPV-150 can establish
persistent infection of hair follicles in immuno-competent individuals. A partial L1 sequence of a putative novel HPV
genotype, related to HPV-150, was identified in a squamous cell carcinoma of the skin obtained from a 64-year old immuno-
compromised male patient.
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Introduction
Papilomaviruses (PVs) are a diverse family of small viruses with
a circular double stranded DNA genome, which are etiologically
linked with several skin and mucosal epithelial lesions of animals
and humans. They are hierarchically classified into categories
designated as genera, species and genotypes [1]. To date, full
genomes of more than 200 PV genotypes have been publicly
deposited, of which roughly 150 have been detected in humans
and are referred to as human PVs or HPVs [1,2]. Currently,
HPVs are classified into five genera: Alpha-, Beta-, Gamma-, Mu-
and Nupapillomavirus [1].
According to the 2004 guidelines for PV nomenclature,
published by the Study Group of Papillomaviruses of the
International Committee on Taxonomy of Viruses (ICTV), in
order to be officially recognized as a unique genotype, a candidate
PV isolate must differ by at least 10% of its complete gene coding
for the major capsid protein (L1 gene) from all other known
genotypes, and its complete genome must be sequenced and
deposited in the form of clones to the Reference Centre for
Papillomaviruses in Heidelberg, Germany [2]. The guidelines
issued in 2010 have refrained from strict identity boundaries and
have suggested instead the introduction of phylogenetic relation-
ships as a guiding criterion [1]. Traditionally, PV genomic
sequences have been obtained directly from epithelial lesions,
using cloning methods, which are mainly suitable for character-
ization of HPV genotypes present in clinical samples in high viral
copy numbers [2]. As the field of molecular biology evolved,
polymerase chain reaction (PCR), rolling circle amplification,
whole genome amplification and, recently, shotgun sequencing
have been added to the repertoire of methods used in
identification of novel PVs [3,4]. These technologies have enabled
the identification and characterization of many recently identified
PVs, especially those present in minute quantities in clinical
samples.
Cutaneous HPV genotypes are found within all five PV genera
that contain HPVs. They are ubiquitously present in human skin
and in the hair follicles of immuno-competent individuals [5–7],
but can occasionally cause various, predominantly benign skin
lesions, including cutaneous warts, e.g. common warts or verrucae
vulgaris [8]. In hosts with primary immuno-deficiency or with a
genetic predisposition, cutaneous HPVs - especially Betapapilloma-
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benign and malignant tumors in patients with the hereditary
disease epidermodysplasia verruciformis [9]. In immuno-suppressed
patients, such as renal transplant recipients, infection with
cutaneous HPVs can similarly lead to the development of various
benign and malignant skin tumors [10–14]. Additionally, several
Betapapillomavirus HPVs, such as HPV-22, HPV-38, HPV-92 or
HPV-96, have been etiologically linked with the development of
squamous cell carcinoma of the skin [15–18]. Several cutaneous
HPVs have also been linked with actinic keratosis, Bowen’s disease
and non-melanoma skin cancer in connection with UV-damage in
immuno-competent hosts [19,20].
In the last decade, several studies have shown that HPV DNA
can be recovered from healthy skin in humans from very early
stages of life [6,21], that skin infections with multiple HPV
genotypes are very common [7,22,23] and that several recently
identified cutaneous HPVs may not be associated with any clinical
manifestations [5,24]. In view of these facts, the clinical
significance of any novel HPV genotype needs to be carefully
examined.
In this study, two novel HPV genotypes: HPV-150 and HPV-
151, isolated originally from eyebrow hair follicles (isolates SIBX1
and SIBX2, respectively) and initially characterized by our group
in 2005 [25], were fully cloned, sequenced and characterized. In
addition, two quantitative type-specific real-time PCRs were
developed and a representative collection of HPV-associated
benign and malignant neoplasms and hair follicles was tested in
order to assess the tissue predilection and clinical significance of
the novel HPV genotypes.
Materials and Methods
The original isolates of HPV-150 (SIBX1) and HPV-151
(SIBX2) were obtained from eyebrow hair follicles of two
immuno-competent males, aged 28 and 25 years, respectively,
during our previous study of HPV distribution in eyebrow hair
follicles of patients with genital warts [25]. The original SIBX1
positive eyebrow hair follicle sample was used for cloning HPV-
150 [25], and a SIBX2 positive sample of scrotal hair, obtained in
2003 from a healthy 23-year-old male individual was used for
cloning of HPV-151 [7]. In both cases, DNA was isolated from
clinical samples by using a High Pure PCR Template Preparation
Kit (Roche Diagnostics GmbH, Mannheim, Germany), according
to the manufacturer’s instructions.
Whole genome amplification (WGA) of both HPV-150 and
HPV-151 was performed prior to PCR amplification, by using an
Illustra
TM TempliPhi 100 Amplification Kit (GE Healthcare,
Amersham, UK), according to the manufacturer’s instructions.
Following the amplification, the WGA product was diluted 200x
fold with PCR-grade H2O.
Amplification, sequencing and cloning of HPV-150
Primers for the reverse long template PCR of HPV-150 were
constructed manually on the basis of the previously obtained 373-
bp sequence of the HPV-150 L1 gene (GenBank Acc. No
AJ606880). A 7,367-bp PCR product of HPV-150 was generated
using primer pair X1-longF and X1-longR (Table S1) and the
Expand Long Template PCR System (Roche Applied Bioscience,
Mannheim, Germany) on a PE9700 Thermo Cycler (Perkin Elmer
Applied Biosystems Inc, Foster City, CA).
PCR was carried out in a 25 ml reaction volume containing 5 ml
of diluted WGA product, 2.5 mlo f1 0 6Expand Long Template
buffer 2 with 27.5 mM MgCl2, 500 mM of dNTPs, 0.75 U of
Expand Long Template Enzyme Mix, and 3 pmol of each primer.
The thermal cycler program was set to 2 min at 94uC, followed by
40 cycles consisting of 10s at 94uC, 30 s at 53uC, and 8 min at
68uC. The final extension step was performed at 68uC for 10 min
and the reaction mixtures were then cooled to 4uC.
Initial sequencing of the 7,367-bp HPV-150 PCR fragment was
done by primer walking (primers are listed in Table S1) using the
ABI PrismH 310 Genetic Analyzer System (Applied Biosystems),
and Big DyeH Terminator 1.1 Cycle Sequencing Kit (Applied
Biosystems), according to the manufacturer’s instructions.
In order to clone the complete genome of HPV-150, two
overlapping blunt-end PCR products of sizes 3,465-bp and 4,375-
bp were generated using primer pairs X1F18 and X1R18; and
X1F5 and X1R5, respectively (Table S1). Both blunt-end PCR
products were generated using KOD Xtreme
TM Hot Start DNA
Polymerase (Toyobo Novagen, EMD Biosciences Inc., San Diego,
CA).
PCR was carried out in a 25 ml reaction volume containing 1 ml
of diluted WGA product, 12.5 mlo f2 6 Xtreme Buffer, 500 mM
(each) of dNTPs, 0.02 U of KOD Xtreme
TM Hot Start DNA
Polymerase, and 0.6 pmol of each primer. The thermal cycler
program was set to 2 min at 94uC, followed by 40 cycles consisting
of 10 s at 94uC, 30 s at 60uC, and 3 to 6 min at 68uC. Following
amplification, the reaction mixtures were cooled to 4uC.
Before cloning, PCR products were excised and purified from
1% agarose gel using a GeneJET
TM Gel Extraction Kit
(Fermentas, Vilnius, Lithuania). Plasmids containing overlapping
PCR products of HPV-150 were prepared using a CloneJET
TM
PCR Cloning Kit (Fermentas), according to the manufacturer’s
instructions. A TransformAid
TM Bacterial Transformation Kit
(Fermentas) was used to transform E.coli strain JM107 with the
HPV-150 clones, according to the manufacturer’s instructions.
Plasmid clones isolated from the transformed overnight
bacterial culture with a GeneJET
TM Plasmid Miniprep Kit
(Fermentas) were checked for correct HPV inserts by size analysis
and sequencing with pJET1.2 sequencing primers, according to
the manufacturer’s instructions.
Sequencing by primer walking was carried out for both clones,
confirming the full genome sequence of HPV-150. The obtained
sequences were additionally confirmed by commercial sequencing
of the selected clones at Macrogen Inc. (Seoul, Korea) and at
Microsynth AG (Balgach, Switzerland).
All primers used in the study were designed manually and
checked for Tm and secondary structures using NetPrimer
(Premier Biosoft International) and TIB-Molbiol (Berlin, Ger-
many) free web-based software. The ‘Primer Pair Specificity
Checking Parameters’ function of Primer-BLAST (NCBI) was
used in order to check for the specificity of the primers.
Amplification, sequencing and cloning of HPV-151
In the case of HPV-151, the primers initially constructed on the
basis of the previously obtained 367-bp sequence of the HPV-
151 L1 gene (GenBank Acc. No AJ606879) failed to amplify the
remainder of the genome. In order to solve this problem,
additional degenerate primers were designed, based on the
genome of HPV-22, the genotype which was most closely related
to HPV-151. An initial assessment of the primers was done by
short PCR using the DreamTaq
TM Green PCR Master Mix (2X)
(Fermentas UAB - Thermo Fisher Scientific, Vilnius, Lithuania),
following the manufacturer’s instructions. The amplified DNA was
examined by gel electrophoresis and several degenerate primer
pairs produced PCR products of the expected size, ranging from
100 to 1,328-bp. Following sequencing of these short amplicons,
several additional primers, specific for the novel genotype HPV-
151, were designed (Table S1). Finally, a 6,256-bp fragment of the
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and X2-longR2, designed on the basis of the sequence obtained
using degenerate primer pair HPV22-L1f1mix and HPV22-L1-
r1mix (Table S1), and the Expand Long Template PCR System
on a PE9700 Thermo Cycler.
PCR was carried out in a 25 ml reaction volume containing 1 ml
of diluted WGA product, 2.5 mlo f1 0 6Expand Long Template
buffer 2 with 27.5 mM MgCl2, 500 mM of dNTPs, 0.75 U of
Expand Long Template Enzyme Mix and 3 pmol of each primer.
The thermal cycler program was set to 2 min at 94uC, followed by
40 cycles consisting of 10 s at 94uC, 30 s at 55uC, and 7 min at
68uC. The final extension step was performed at 68uC for 7 min
and the reaction mixtures were then cooled to 4uC.
Initial sequencing of the 6,256-bp HPV-151 PCR fragment was
done by primer walking with the primers listed in Table S1.
For cloning HPV-151, two overlapping blunt-end PCR
products of sizes 2,785-bp and 5,481-bp were generated using
primer pairs X2F17 and X2R17; and X2F3 and X2R3,
respectively (Table S1) by using KOD Xtreme
TM Hot Start
DNA Polymerase (Toyobo Novagen, EMD Biosciences Inc.).
PCR conditions and the entire further cloning and sequencing
procedure for HPV-151 were the same as described above for
HPV-150.
ORF and phylogenetic analysis
All partial sequences obtained for HPV-150 and HPV-151 were
assembled using ContigExpress of Vector NTI Advance
TM v11.0
(Invitrogen, Carlsbad, CA). The open reading frames (ORFs) of
HPV-150 and HPV-151 were determined using the ORF finder
function of Vector NTI Advance
TM v11.0 and were additionally
confirmed by genome organization analysis and comparison with
closely related HPV genotypes using the BioEdit Sequence
Alignment Editor [26].
The phylogenetic relationships of HPV-150 and HPV-151
within the PV family were determined based on the L1 gene.
Briefly, L1 nucleic acid sequences were converted to protein
sequences and aligned using MAFFT v6.832b (http://mafft.cbrc.
jp/alignment/software) [27], reverse translated using Pal2Nal
(http://www.bork.embl.de/pal2nal/) [28] and filtered using
Gblocks (http://molevol.cmima.csic.es/castresana/Gblocks.html)
[29,30]. Maximum likelihood phylogenetic inference was con-
ducted using RAxML version v7.2.8 [31–33] alpha (PTHREADS
version) on an 2x CPU 6 core AMD Opteron 2431 with 12 GB
RAM DDR2-800 (kindly provided free of charge by ABAKUS
plus, Kranj, Slovenia). A generalized time-reversible (GTR) model
with four gamma discrete rate categories and three partitions, one
per codon position, was used for the analysis. One thousand
bootstrap replicates were generated to determine node support for
the best tree.
HPV-150 and HPV-151 type specific real-time PCRs
Primers and a probe specific for HPV-150 were chosen within
the L1 gene by using the on-line ProbeFinder software (Roche
Applied Science), resulting in a PCR product of 60-bp in length.
Primers RT-150-F (59- AGGCCTTACCTTGTGCTGAA -39,
HPV-150 nucleotide positions 6,355 to 6,374) and RT-150-F (59-
TTAATTCTAAAGGAGGACATGAACC -39, HPV-150 nucle-
otide positions 6,390 to 6,414), together with FAM-labeled
Universal Probe #50 (Roche Applied Science) were used for
HPV-150 specific real-time PCR.
Primers and a probe specific for HPV-151 were chosen within
the L1 gene by using the on-line ProbeFinder software (Roche
Applied Science), resulting in a PCR product of 60-bp in length.
FAM-labeled Universal Probe #127 (Roche Applied Science) was
used together with primers RT-151-F (59- ATCAGCAACA-
GATGGAGCAA -39, HPV-151 nucleotide positions 5,838 to
5,857) and RT-151-R (59- GCTCTATACTGGTTCCCTGA-
CAC -39, HPV-151 nucleotide positions 5,875 to 5,897) for HPV-
151 specific real-time PCR.
The plasmid reference clones of HPV-150 and HPV-151,
containing the L1 sequence, were used to optimize the real-time
PCR conditions. Plasmid DNA concentration was quantified using
a NanoDrop ND-1000 spectrophotometer (Nanodrop Technolo-
gies, Oxfordshire, UK) and the number of plasmid copies/ml was
calculated using the equation of Whelan et al. [34].
The optimized real-time PCR reaction mixture for both type-
specific real-time PCRs contained 10 ml of LightCyclerH Probes
Master 2x conc. (Roche Applied Science), 0.2 mM of each primer,
0.05 mM of Universal Probe #50 or #127 (Roche Applied
Science), 1U of LightCyclerH Uracil-N-Glycosylase (Roche
Applied Science), sample DNA and water up to a final volume
of 20 ml. The assays were performed on a LightCyclerH 480
(Roche) under the following conditions: Uracil-N-Glycosylase
activation at 40uC and pre-incubation at 95uC for 10 min each,
followed by 45 cycles of 95uC for 10 s (denaturation) and 59uC for
30 s (annealing) and 72uC for 1 s (extension). Acquisition of the
fluorescence signal was performed in single mode during the
annealing step of each cycle. The final cooling step consisted of a
10 s hold at 40uC. The conditions of the real-time PCR for HPV-
150 and HPV-151 were intentionally identical, since this allowed
simultaneous testing of samples on the LightCyclerH 480 (Roche).
To evaluate the linearity of the assays, triplicate ten-fold serial
dilutions of the reference plasmids of HPV-150 and HPV-151
were prepared in 1.5 ml DNA LoBind tubes (Eppendorf,
Hamburg, Germany) using a water solution with carrier RNA
(1 mg/ml). The limits of detection of the assays were determined by
testing 15 replicates of the reference plasmid dilutions correspond-
ing to an input of 25, 13, 6, 3, 1.5, 0.8 and 0.4 copies per reaction.
The specificity and cross-reactivity of the assays were tested
using 10
7 to 10
8 copies of synthetic partial L1 sequences (inserted
into plasmid pUC57, by Genscript, Piscataway, USA) of the
following Betapapillomaviruses: HPV-9, HPV-15, HPV-17, HPV-22,
HPV-23, HPV-37, HPV-38, HPV-80, HPV-100, HPV-111,
HPV-113, HPV-120, HPV-122, HPV-92 and HPV-96.
Clinical samples
The tissue predilection and clinical significance of HPV-150 and
HPV-151 were assessed on a representative collection of HPV-
associated benign and malignant neoplasms and hair follicles. The
DNA was isolated from a total of 540 samples obtained from the
same number of patients, including tissue samples of histologically
confirmed genital warts (71), laryngeal papillomas (78), cervical
squamous cell carcinomas (100), common warts (101), squamous
cell carcinoma (SCC) of the skin (52), basal cell carcinoma (BCC)
of the skin (49) and hair follicles (89), as described previously
[7,25,35-38]. The quality of isolated DNA and absence of PCR
inhibitors were checked by amplification of a 110-bp fragment of
human beta-globin, as described previously [36]. The number of
human cells per ml of clinical sample in samples positive for HPV-
150 or HPV-151 was calculated from the beta-globin concentra-
tion, as described previously [17], and used to determine the ratio
between the number of viral genomes and human cells. All positive
results of the HPV-150 and HPV-151 real-time PCRs were
confirmed by sequencing.
The presence of additional HPV genotypes in HPV-150 and/or
HPV-151 positive samples was determined using two commercial
line-probe assays: INNO-LiPA HPV Genotyping Extra (Innoge-
netics, Gent, Belgium), which allows identification of 28 different
Characterization of HPV-150 and HPV-151
PLoS ONE | www.plosone.org 3 July 2011 | Volume 6 | Issue 7 | e22529Alphapapillomavirus genotypes; RHA skin (beta) HPV (Diassay B.V.,
Rijswijk, The Netherlands), which allows identification of 26
different Betapapillomavirus genotypes, and additionally by consen-
sus GP5+/6+ in-house PCR and sequencing of PCR products
[39].
Ethics Statement
None of the 540 clinical samples tested were collected solely for
the purpose of this study. All samples included in the study were
collected in compliance with the Helsinki Declaration. Samples of
cervical cancer, hair follicles, genital warts and common warts
were collected prospectively in our previous studies. These studies
were approved by the Ethics Committee of the Ministry of Health
of the Republic of Slovenia (consent references 34/11/06, 83/11/
09, 174/05/09, 97/11/09 and 100/12/09) and written informed
consent was obtained from each patient. Samples of laryngeal
papillomas, squamous cell carcinoma and basal cell carcinoma of
the skin were retrieved from the tissue collection of paraffin-
embedded samples of the Institute of Pathology, Faculty of
Medicine, University of Ljubljana. Approval from the Institutional
Review Board of the Institute of Pathology, Faculty of Medicine,
University of Ljubljana was obtained prior to starting work on
samples included in this study. In accordance with the national
legislation of the Republic of Slovenia, no informed consent is
needed for research on archival clinical samples. In order to
protect the identity of the patient, all archival clinical samples used
in the study were coded and tested anonymously. The only
available data were patient gender, age and immune status (if
collected during the original study).
Results and Discussion
Partial L1 sequences of HPV-150 (SIBX1; 373-bp) and HPV-
151 (SIBX2, 367-bp) were deposited in GenBank in March 2005
under Acc. Nos. AJ606880 and AJ606879, respectively. The four
reference clones, covering the full genomes of HPV-150 and HPV-
151, were deposited in March 2010 in the Reference Centre for
Papillomaviruses, Heidelberg, Germany, where their sequences
were independently confirmed and the two genotypes were
officially named in April 2010.
The genome of HPV-150 has a total length of 7,436-bp, with a
GC ratio of 39.70%, and is deposited in GenBank under Acc.
No. FN677755. The genome of HPV-151 has a total length of
7,386-bp, with a GC ratio of 39.79%, and is deposited in GenBank
under Acc. No. FN677756.
ORF analysis and sequence alignment comparisons showed both
HPV-150 and HPV-151 to have the typical genomic organization
of HPVs and to contain at least six viral genes: E6, E7, E1, E2, L2
and L1, as well as possibly a gene for the E4 protein (Figure 1). In
addition to the mentioned ORFs, the genomes of both new
genotypes contain a non-coding upstream regulatory region (URR)
or long control region (LCR) located between the L1 and E6 genes,
spanning 416-bp in HPV-150 (genomic positions 7,371 to 350) and
322-bp in HPV-151 (genomic positions 7,213 to 148) (Figure 2).
The LCRs ofbothHPV-150 and HPV-151lack the conserved M29
and M33 motifs [40] which are typical for members of
Betapapillomavirus species 1 [41] but are absent in other Betapapillo-
mavirus species [42]. As in other members of Betapapillomaviruses, the
intergenic region located between E2 and L2 genes is very short (51-
bp in HPV-150 (genomic positions 4,219 to 4,269) and 84-bp in
HPV-151 (genomic positions 4,008 to 4,091)) and does not encode
for an E5 gene.
HPV-150 and HPV-151 contain two regular zinc binding
domains (CxxC(x)29CxxC) within their E6 protein, at amino-acid
positions 24 and 98; and 27 and 101, respectively (Figure 3). Both
genotypes also contain one regular zinc binding domain
(CxxC(x)29CxxC) within their E7 protein, at amino-acid positions
50 and 53, respectively. However only HPV-150 also contains the
regular pRb-binding core sequence (LxCxE) at amino-acid
position 24 of E7 (Figure 3). Unlike other members of
Betapapillomavirus species 2, HPV-151 does not contain the regular
pRb-binding core sequence (LxCxE) within its E7 protein
(Figure 3).
Phylogenetic analyses using the L1 gene sequences of a
representative selection of 200 PVs place both HPV-150 and
HPV-151 within the Betapapillomavirus genus (Figure 4). As shown
in Figure 4, the closest relative of HPV-150 is HPV-96 (79.59%
nucleotide (nt) identity in the L1 gene; distance in substitutions per
site for L1; 0.264440 and 0.103792 for nt and for amino-acid (aa),
respectively). HPV-96 belongs to Betapapillomavirus species 5 and
was originally isolated from a SCC of the skin [18]. The next
phylogenetically closest genotype to HPV-150 and HPV-96 is
HPV-92, which belongs to Betapapillomavirus species 4, and was
originally isolated from a BCC of the skin [16]. Since these three
genotypes seem to have evolved through intra-host duplication
[43] and two of them show at least some carcinogenic potential,
the ancestral genotype from which these genotypes were derived
may have itself been an oncogenic HPV genotype.
As shown in Figure 4, HPV-151 appears to be phylogenetically
nested within Betapapillomavirus species 2, with HPV-22 being its
closest relative (86.98% nt identity for the L1 gene; 0.164208 and
0.084639 distance in substitutions per site for L1 nt and aa,
respectively). HPV-22 was originally isolated from chest macules
[15]. Currently, Betapapillomavirus species 2 encompasses 17 HPV
genotypes isolated from humans, making it one of the largest
species among PVs. The generation of such viral diversity has
probably occurred through intra-host duplication events, which
may reflect multiple ways of succeeding in adaptation to the
human host [43]. An example of this capacity to establish
infection in multiple ways can be seen from the fact that
particular genotypes of Betapapillomavirus species 2 have been
found in lesions ranging from macules and other benign skin
lesions, to actinic keratosis, BCC and SCC of the skin, and even
head and neck and esophageal carcinoma, as in the case of HPV-
100 [44].
In order to assess the biological and clinical importance of the
novel HPV genotypes, two quantitative HPV-150 and HPV-151
type-specific PCR assays were developed. The standard curves of
both assays showed an excellent correlation coefficient (R
2=1.00)
between the Ct (threshold) and the log of starting viral copy
number across at least seven orders of magnitude. The 95% limits
of detection determined by Probit analysis using the PASW
Statistics 18 program (SPSS GmbH Software, Munich, Germany)
were 7.3 copies/reaction (range 5.6 to 11.4) and 3.4 copies/
reaction (range 2.5 to 6.0), for the HPV-150 and HPV-151 assays,
respectively. For HPV-150 assay, the intra- and inter-assay
coefficient of variation (CV (%) = (st.dev/mean Ct)6100) were
0.55 and 1.43 for 100 copies per reaction, respectively, and 1.73
and 1.81 for 10 copies per reaction, respectively, and correspond-
ing values for HPV-151 assay were 0.81 and 1.54 for 100 copies
per reaction, respectively, and 1.02 and 1.98 for 10 copies per
reaction, respectively. Both assays showed no cross-reactivity with
any of the tested non-targeted HPV genotypes.
Using the developed type-specific PCRs, a representative
collection of HPV-associated benign and malignant neoplasms
and hair follicles was tested for the presence of HPV-150 and
HPV-151. The sample collection was chosen to represent various
sites of HPV infection (mucosal/cutaneous) and possible outcomes
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of samples thus included the most important HPV-associated
malignant neoplasms of mucosal (cervical squamous cell carcino-
ma) and cutaneous (SCC and BCC of skin) origin, and the most
important HPV-associated benign neoplasms of mucosal (genital
warts, laryngeal papillomas) and cutaneous (common warts) origin.
In addition, we tested hair follicles, which are commonly used as
the best approximate to skin biopsies, to examine the prevalence of
Betapapillomaviruses in healthy skin [45,46] and are known to be a
main reservoir of commensal HPV genotypes in immuno-
competent individuals [5–7].
As shown in Table 1, none of the 249 mucosal tissue samples
tested were positive for HPV-150 and HPV-151, indicating little, if
any, mucosal tropism of both novel HPV genotypes.
Of the 101 samples of common warts tested, four samples
(4.0%) contained HPV-150, indicating the cutaneous tropism of
this genotype (Table 1). Of HPV-150 positive common warts,
three samples contained at least one additional HPV genotype
(samples 1, 2 and 4, Table 2): HPV-27 from Alphapapillomavirus
species 4, a well known genotype capable of causing common
warts; HPV-5 and HPV-14, cutaneotropic members of Betapa-
pillomavirus species 1; and HPV-15 belonging to Betapapillomavirus
species 2 – all three later being genotypes associated with the
development of cutaneous tumors in immuno-suppressed patients
or patients with epidermodysplasia verruciformis. Due to the presence of
more than one HPV genotype in these lesions, the development of
common warts could not be conclusively attributed to HPV-150.
In contrast, in the fourth HPV-150 positive common wart (sample
Figure 1. Genomic organization of HPV-150 and HPV-151 showing genomic positions of viral genes E6, E7, E1, E2, L1, L2, and the
non-coding regions located between L1 and E6 (LCR); and E2 and L2 (dotted line).
doi:10.1371/journal.pone.0022529.g001
Figure 2. Characteristic features of the long control region (LCR) of HPV-150 and HPV-151, showing genomic locations of E2
binding sites (ACC-N5-7-GGT), polyadenilation sites (AATAAA), and TATA signals (TATAAA or TATA(A/T)A(A/T).
doi:10.1371/journal.pone.0022529.g002
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despite the use of several HPV genotyping assays, targeting a
range of Alphapapillomavirus and Betapapillomavirus genotypes,
indicating a possible causative role of HPV-150 in the develop-
ment of this particular common wart. Although the HPV-150 viral
load was relatively low (1/31 viral genomes/No. human cells) our
finding is in agreement with recent studies which showed that viral
load of Betapapillomaviruses associated with cutaneous warts is
substantially lower than that of Alphapapillomaviruses (HPV-3, HPV-
27, HPV-57) associated with similar lesions (1/2 to 1/10 000 viral
genomes/No. human cells) [47]. However, further research is
needed in order to reach any final conclusions on the ability of
HPV-150 to cause common warts in absence of other factors.
As shown in Table 1, HPV-150 was detected in four (4.0%) of
the 101 samples of malignant skin tumors tested, further
supporting cutaneous tropism of HPV-150. Similarly to the
common warts, several additional cutaneous genotypes from
Betapapillomavirus genus were present in three out of four HPV-150
positive samples of malignant skin tumors included in the study
(samples 6–8, Table 2), greatly complicating the interpretation of
our findings. The interpretation of our results is additionally
complicated by the difference in viral loads observed between an
abortive HPV infection leading to malignant transformation of the
skin, which typically involves Betapapillomavirus genotypes present
in minute quantities [13,18,48–50] and on the other side the
productive HPV infection of the skin resulting in benign tumors,
such as common warts, which usually harbor viruses in higher
concentration [47]. Such differences make it near impossible to
distinguish causative or ‘driver’ HPV genotypes from commensal
or ‘passenger’ HPV genotypes, also present on the lesion and/or
the surrounding skin [48]. Thus, although the HPV-150 was the
only HPV genotype detected in a single case of SCC of the skin
(sample 5, Table 2), due to its presence in very low quantity (1/
57,950 viral genomes/No. human cells), further studies are
needed in order to establish if HPV-150 is a causative or
commensal genotype in sporadic cases of the SCC of the skin.
As shown in Table 1, HPV-150 was also found in three (3.4%)
out of 89 hair follicle samples tested (Table 1), finally confirming
cutaneous tropism of HPV-150.
Long term persistent HPV infection is a key requirement for the
development of HPV-related anogenital cancers, but its role is less
clear in the case of HPV-related skin cancer [13,20,48-50]. In
order to determine whether HPV-150 can establish persistent
infection, seven hair follicle samples collected over the course of
one year from one of the HPV-150 positive individuals were tested
using HPV-150 type-specific PCR. In this immuno-competent 22-
year-old male, HPV-150 was detected in all seven hair follicles
tested, confirming its potential for persistent infection. However,
similarly to the majority of other Betapapillomavirus infections in
immuno-competent individuals [22-24], no obvious epithelial
lesions were recorded as a result of the persistence of HPV-150
in our patient during 12 months of follow-up.
Of the 101 samples of common warts tested, four samples
(4.0%) contained HPV-151, indicating its cutaneous tropism
(Table 1). Of HPV-151 positive common warts, two samples
contained at least one additional Betapapillomavirus genotype
(samples 12 and 14, Table 3): HPV-9, the type species of
Betapapillomavirus species 2; HPV-19, HPV-36 and HPV-93 of
Betapapillomavirus species 1; and HPV-49 of Betapapillomavirus
species 3. Since all listed genotypes have cutaneous tropism and
are etiologically associated with the development of cutaneous
tumors in immuno-suppressed patients or patients with epidermo-
dysplasia verruciformis, these two common warts could not conclu-
sively be attributed etiologically to HPV-151. In contrast, two
HPV-151 positive common wart samples (samples 13 and 15,
Table 3) did not contain any additional HPV genotypes, indicating
a possible causative role of HPV-151 in the development of these
two common warts. Both samples had viral loads (1/493 and 1/
Figure 3. Amino acid alignment of HPV-150 and HPV-151 E6 and E7 proteins with corresponding proteins of closely related
genotypes from Betapapillomavirus species 2, 4 and 5. The locations of zinc-binding domains (CxxC(x)29CxxC) are indicated by black boxes, and
the location of the pRb-binding core sequence (LxCxE) is indicated with a blue box.
doi:10.1371/journal.pone.0022529.g003
Characterization of HPV-150 and HPV-151
PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e22529103 viral genomes/No. human cells, respectively) of magnitude
characteristic for Betapapillomavirus genotypes in common warts
[47], however the final contribution of HPV-151 to the
development of these lesions requires further studies.
As shown in Tables 1 and 3, HPV-151 was detected in four
(4.0%) of the 101 malignant skin tumor samples and in three
(3.4%) of 89 hair follicle samples tested, finally confirming the
cutaneous tropism of this novel HPV genotype. In the majority of
the HPV-151 positive samples, several other HPV genotypes were
identified (Table 3).
In the single HPV-151 positive BCC, where no other HPV
genotypes were present (sample 16, Table 3), the viral load was
relatively low (1/691 viral genomes/No. of human cells). Such
minute viral load is consistent with values described previously for
other Betapapillomaviruses in non-melanoma skin cancer [18,48,49],
and given the advanced age of the patient (84 years) it is possible
Figure 4. A consensus phylogenetic tree of 200 PV based on nucleotide sequences of the L1 gene. Numbers at nodes show maximum
likelihood bootstrap support (%) above 50. Betapapillomavirus species numbers are indicated above the corresponding genotypes.
doi:10.1371/journal.pone.0022529.g004
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the BCC in question. However, further studies are required in
order to finally establish the causative role of HPV-151 in the
development of BCC of the skin.
Interestingly, one sample of BCC of the skin (sample 8, Tables 2
and 3) contained both novel HPV genotypes: HPV-150 and HPV-
151, but not other HPV genotypes. Similarly, one sample of SCC
of the skin (sample 6, Tables 2 and 3) contained both HPV-150
and HPV-151 in addition to HPV-37. In both skin cancers, the
viral loads per number of human cells were substantially higher for
HPV-151 than for HPV-150, but the significance (if any) of these
findings remains to be determined.
In addition to full characterization of two novel HPV genotypes,
a putative novel HPV genotype, phylogenetically related to HPV-
150, was identified in a tissue sample of SCC of the skin obtained
from a 64-year old male immuno-compromised patient, together
with HPV-9, the type species genotype of Betapapillomavirus species
2. The 354-bp sequence of L1 gene of this putative novel HPV
genotype (isolate SI-HPV-Beta5; GenBank Acc. No. FR822732)
showed 90.68% nt identity with the corresponding part of the L1
sequence of HPV-150 but its other characteristics remain to be
determined in future studies.
Conclusions
The cloning and full characterization of two novel Betapapillo-
maviruses HPV-150 and HPV-151, as well as the partial
identification of a putative novel HPV genotype closely related
to HPV-150 (isolate SI-HPV-Beta5), improves our knowledge of
the diversity of Betapapillomaviruses infecting humans. HPV-150 and
HPV-151 belong phylogenetically within the Betapapillomavirus
genus and are most closely related to HPV-96 and HPV-22,
respectively. Both novel genotypes are relatively rare, most likely
lack mucosal tropism and have clear cutaneous tropism. HPV-150
can establish persistent infection of hair follicles in immuno-
Table 1. Clinical samples tested for the presence of HPV-150 and HPV-151.
Tissue type Sample type
No. of samples
tested
No. (%) of HPV-150
positive samples
No. (%) of HPV-151
positive samples
Mucosal
Genital warts 71 0 0
Laryngeal papillomas 78 0 0
Cervical cancer 100 0 0
Cutaneous
Common warts 101 4 (4.0) 4 (4.0)
Squamous cell carcinoma of the skin 52 3 (5.8) 1 (1.9)
Basal cell carcinoma of the skin 49 1 (2.0) 3 (6.1)
Hair follicles
89 3 (3.4) 2 (2.2)
Total 540 11 (2.0) 10 (1.9)
doi:10.1371/journal.pone.0022529.t001
Table 2. Characteristics of HPV-150 positive samples and patients.





cutaneous 1 Common wart 15 Male 1/15 HPV-27
cutaneous 2 Common wart 81 Female 1/212 HPV-5, HPV-14, HPV-15
cutaneous 3 Common wart 90 Male 1/31 None
cutaneous 4 Common wart 16 Male 1/12 HPV-5
cutaneous 5 Squamous cell carcinoma
of the skin
82 Male 1/57950 None
cutaneous 6 Squamous cell carcinoma
of the skin
80 Male 1/9508 HPV-151, HPV-37
cutaneous 7 Squamous cell carcinoma
of the skin
86 Male 1/140 HPV-8, HPV-75
cutaneous 8 Basal cell carcinoma of
the skin
81 Female 1/22638 HPV-151
hair follicle 9 / 29 Male Nd HPV-6, HPV-8, HPV-9, HPV-17, HPV-21
hair follicle 10 / 27 Male Nd None
hair follicle 11 / 52 Female Nd HPV-8, HPV-14, HPV-38, HPV-93
Nd – Not determined.
doi:10.1371/journal.pone.0022529.t002
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in sporadic cases of common warts, SCC and BCC of the skin
preferably in elderly immuno-competent individuals, as both single
and multiple infections with viral loads ranging from 1/12 to 1/
57,950 viral genomes/No. of human cells.
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